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Within European cancer registration areas, there is a sub-
stantial variation in testicular cancer incidence, with a ratio
around a factor 10 between the highest rates registered in
Switzerland, Denmark and Norway, and the lowest ones in
Southern Italy, Spain and Eastern countries. Part of the
variation is possibly due to registration accuracy, since the
differences were lower in relation to mortality, and the pat-
tern was somewhat different, the highest rates being observed
in East Germany, Hungary and Czechoslovakia, and the
lowest ones in Greece, Portugal and Spain (Levi et al., 1989).
The main reason for the elevated mortality in Eastern count-
ries is however the lack of availability of efficacious treat-
ment, particularly cisplatinum, which have substantially
reduced mortality over the last decade (Osterlind, 1986;
Boyle et al., 1990), although the time trends in various
countries were somewhat different even before the identifi-
cation of efficacious chemotherapy. On the other hand, the
disease is uniformly rare in Black populations, whether in
Africa or USA (Schottenfeld et al., 1980; Van den Eeden &
Weiss, 1989).
The age curve of the disease has two peaks, one in the
twenties and one later in life (Clemmesen, 1968), following
the relative frequency of different histological types (since
teratomas have an earlier peak incidence than the more
frequent seminomas, and lymphomas are more frequent at
older ages) and possibly reflecting the role of different risk
factors (Boyle et al., 1987; Pike et al., 1987). Further, there is
evidence that the incidence is now increasing predominantly
in young men, and specifically for teratomas (Boyle et al.,
1987).
Cryptorchidism is the only one established risk factor for
the disease, with relative risks of the order of 2-4, not
restricted to the retrieved testis, and a population attributable
risk of approximately 10% in North America (Schottenfeld
et al., 1980; Pottern et al., 1985; Motris Brown et al., 1987;
Strader et al., 1988). Further, the disease is more frequent in
higher social classes (Davies, 1981). Other potential factors,
such as in utero exposure to oestrogens, or occupational
exposure to farming or chemical substances, and marital
status have been studied (Ross et al., 1979; Beard et al., 1984;
Mills et al., 1984; Newell et al., 1987; Pearce et al., 1987;
Bernstein et al., 1988; Levi et al., 1988), but there is at
present no clear evidence on their role nor on their potential
impact on the increase of the disease.
In order to present further documentation on the descrip-
tive epidemiology of testicular cancer, we present in this
article incidence and survival data for the Cancer Registry of
the Canton of Vaud, Switzerland. This is one of the cancer
registration areas with highest incidence rates on European
and global scale (Levi et al., 1989).
The data was abstracted from the Vaud Cancer Registry
file, which includes data concerning incident cases of malig-
nant neoplasms in the Canton of Vaud (whose population,
according to the 1980 Census, was about 530,000
inhabitants). Information collected by the registry includes
general demographic characteristics of the patient (age, sex,
municipality of residence), site and histological type of the
tumour according to the Standard International Classifi-
cation of Diseases for Oncology (ICD-O), and time of diag-
nostic confirmation (Levi, 1987).
The series comprises 343 testicular cancers registered from
1974 to 1987. For the present report, cases were grouped into
the following three morphological categories: (1) seminomas
(ICD-O M: 9060-4); (2) teratomas, including embryonal
carcinoma (ICD-O M: 9070-3; 9080-4; 9102); and (3) other
morphologies and clinical tumours.
tumours.
Histological confirmation was obtained for 98% of the
series and tumours discovered from death certificate alone
accounted for about 1% across the period considered.
Overall and 15-44 year age-standardised rates, using the
direct method on the basis of the world standard population,
have been chosen for presentation.
Information on survival is integrated from mortality statis-
tics into the incidence registry database and, for patients who
are 'apparently' alive, through an active follow-up based on
verification of vital status from registries of current residence.
The vital status of each patient has been verified up to 30
June 1989.
The overall age-standardised (world standard) incidence
rate was 8.4/100,000 (4.1 seminoma; 3.6 teratoma; 0.7 other
and clinical), and the truncated 15-44 years was 15.8 (7.3
seminoma; 7.6 teratoma; 0.9 other and clinical). The peak
rate for all histotypes together (over 25/100,000) was reached
in the 25-34 age groups, and occurred earlier for teratomas
than for seminomas. After declining to a bottom rate of
1.2/100,000 in the 60-64 year age group, some increase
(chiefly due to lymphomas and other histotypes) was
observed at older ages.
Rates for the Lausanne conurbation (accounting for about
40% of the population of the whole Canton) were about
60% higher than rural ones (10.7 vs 6.8/100,000, all ages;
18.1 vs 12.9 at ages 15-54). Most of the difference was
accounted for by teratoma alone, rates for seminoma being
similar in urban and rural areas.
Trends in age-standardised incidence rates over the 14-year
calendar period considered are shown in Table I, and 3-year
moving averages for all testicular cancers at all ages and
truncated 15-44 years are plotted in Figure 1. Overall
incidence remained stable in relation both to the overall rates
and to the younger age groups. There was some inconsistent
rise in seminomas and 'other' histotypes, and some decline in
teratomas, but this can be easily accounted for by random
variation alone.
Overall 5-year survival rates increased from 73 to 87%
between 1974-80 and 1981-87 (X2 = 7.56, P <0.01) (Figure
2). Survival improved for seminomas from 84 to 95%, for
teratomas from 68 to 86% and for other histotypes from 32
to 54%.
Some of the results from this study are well established,
such as the bimodal incidence curve of testicular cancer with
an earlier and major peak in the second to third decade, the
younger age distribution for teratomas than for seminomas,
the higher rates in urban than in rural areas, and the im-
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Table I Overall and 15-44 years age-standardised (world) incidence rates for
malignant testicular tumours according to calendar period and histological type
(Cancer Registry of Vaud, Switzerland, 1974-1987)
Age Incidence rates/100,000 males per period of diagnosis
Type group 1974-76 1977-79 1980-84 1985-87
Seminoma All ages 3.5 (32)a 4.2 (37) 4.2 (64) 4.5 (42)
15-44 6.3 (25) 7.4 (28) 7.2 (46) 8.6 (34)
Teratoma All ages 3.9 (31) 3.9 (32) 3.6 (49) 2.7 (23)
15-44 8.6 (30) 8.7 (30) 7.6 (45) 5.6 (20)
Other types All ages 0.4 (4) 0.7 (6) 0.8 (15) 0.9 (8)
and clinical 15-44 0.7 (2) 0.7 (2) 0.9 (5) 1.4 (5)
Total, all All ages 7.9 (67) 8.8 (75) 8.7 (128) 8.1 (73)
morphologies 15-44 15.6 (57) 16.8 (60) 15.8 (96) 15.6 (59)
aNumber of cases is given in parentheses.
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Figure 1 Trends in age-standardised (world) incidence from all
testicular cancers in the Swiss Canton of Vaud, 1974-87 at all
ages and truncated 15-44 years, based on 3-year moving
averages.
proved survival over more recent calendar periods (Clem-
mesen, 1968; 0sterlind, 1986; Boyle et al., 1987, 1990).
The major and original finding from this study is however
the absence of any trend in incidence over the past decades,
together with the fact that the rates registered in this popula-
tion (8.4/100,000) were higher than in other published series.
In comparison, age-adjusted registered incidence rates in the
early 1980s were 3.8 in American Whites (Morris Brown et
al., 1986), approximately 5 in Scotland (Boyle et al., 1987)
and 8.0 in Denmark, after a steady rise from 3.1/100,000 in
1943-47 (Clemmesen, 1968; Osterlind, 1986). The peak in
age-specific rates was just over 10 in South Thames, England,
as compared to 25 in Vaud.
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Figure 2 Survival of 343 malignant testicular tumours according
to period of diagnosis. Cancer Registry of Vaud, Switzerland,
1974-87.
Only rates of blacks from the Surveillance, Epidemiology
and End Results (SEER) Program appeared stable from 1973
to 1984, but an increase of about a third of testicular cancer
incidence in white Americans was registered over the same
calendar period (Van Den Eeden & Weiss, 1989).
This seems therefore to be the first well monitored white
population where stable rates in testicular cancer incidence
have been observed, and it is thus tempting to speculate
whether an asymptote in the rise in testicular cancer will be
reached in other white populations in the near future.
The contribution of the Swiss League against Cancer, Bern, is
gratefully acknowledged.
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